Efficacy, safety, and biomarker changes of B-cell activating factor and A proliferation-inducing ligand-targeted therapies in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials
Journal of Nephrology · 2026
DOI: 10.1093/joneph/aajaf002 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Rafael Dos Santos Borges und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Federal University of Minas Gerais (UFMG), 190 Prof. Alfredo Balena Avenue-Santa Efigênia, Belo Horizonte, MG 30130100, Brazil. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, B-Cell Activating Factor, Tumor Necrosis Factor Ligand Superfamily Member 13. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) are cytokines involved in B-cell activation and survival, contributing to the pathogenesis of IgAN. This meta-analysis aimed to evaluate the efficacy, safety, and biomarkers of BAFF- or APRIL-targeted therapies in patients with IgAN.
Methods
We searched PubMed, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) comparing BAFF- or APRIL-targeted drugs with placebo in adults with IgAN, published up to December 2024 and written in English. Efficacy outcomes were the mean percent change in the 24-hour urine protein-to-creatinine ratio (UPCR) and the mean change in the estimated glomerular filtration rate (eGFR) from baseline. Safety included the incidence of adverse events. The biomarkers we used were changes in serum Gd-IgA1, IgG, IgA, and IgM from baseline. The risk of bias and the certainty of evidence were assessed using RoB v2.0 and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). We used the R software version 4.2.1 for statistics.
Results
Four Phase II RCTs, including 331 patients, were included, with three studies having a low risk of bias, while there were some concerns regarding one study. Compared to placebo, BAFF- or APRIL-targeted drugs significantly reduced 24-hour UPCR (mean difference [MD] −38.94%; 95% confidence interval [CI] −58.98 to −18.90; P = 0.0001; I² = 0%) and significantly improved the eGFR (MD 7.05 mL/min/1.73 m²; 95% CI 3.83 to 10.27; P < 0.0001; I² = 0%). Adverse events did not significantly differ between the study groups. BAFF- or APRIL-targeted drugs significantly decreased serum Gd-IgA1, IgG, IgA, and IgM compared with placebo, indicating lower immune complex formation and response to treatment.
Conclusion
BAFF- or APRIL-targeted therapies appear to be effective and safe in reducing proteinuria in patients with IgAN. PROSPERO registration ID CRD42024598157
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Federal University of Minas Gerais (UFMG), 190 Prof. Alfredo Balena Avenue-Santa Efigênia, Belo Horizonte, MG 30130100, Brazil.
- Faculty of Medicine, Federal University of Pará (UFPA), 1 Augusto Corrêa Street-Guamá, Belém, PA 66075110, Brazil.
- Faculty of Medicine, Federal University of Uberlândia (UFU), 1720 Pará Avenue-Umuarama, Uberlândia, MG 38400902, Brazil.
- Department of Medicine and Department of Molecular Medicine, Università degli Studi di Padova, 2 Via VIII Febbraio, Padova 35122, Italy.
- School of Medicine, University of Passo Fundo (UPF), BR 285 Km 292,7-São José, Passo Fundo, RS 99052900, Brazil.
- Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, UFMG. 190 Prof. Alfredo Balena Avenue-Santa Efigênia, Belo Horizonte, MG 30130100, Brazil.
ORCID-Profile: Rafael Dos Santos Borges, Rodrigo Lara Santos, Luiza Haikal de Paula, Jefferson Manoel Borges Martins, Pedro Antônio Machado Gomes de Sousa, Giovanni Gosch Berton, Ana Cristina Simões E Silva
Zitieren
APA
Dos Santos Borges, R., Lara Santos, R., Haikal de Paula, L., Borges Martins, J. M., Machado Gomes de Sousa, P. A., Gosch Berton, G., & Simões E Silva, A. C. (2026). Efficacy, safety, and biomarker changes of B-cell activating factor and A proliferation-inducing ligand-targeted therapies in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. Journal of Nephrology. https://doi.org/10.1093/joneph/aajaf002
Vancouver
Dos Santos Borges R, Lara Santos R, Haikal de Paula L, Borges Martins JM, Machado Gomes de Sousa PA, Gosch Berton G, et al. Efficacy, safety, and biomarker changes of B-cell activating factor and A proliferation-inducing ligand-targeted therapies in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. Journal of Nephrology. 2026. doi:10.1093/joneph/aajaf002
BibTeX
@article{DosSantosBorges2026,
author = {Dos Santos Borges, Rafael and Lara Santos, Rodrigo and Haikal de Paula, Luiza and Borges Martins, Jefferson Manoel and Machado Gomes de Sousa, Pedro Antônio and Gosch Berton, Giovanni and Simões E Silva, Ana Cristina},
title = {Efficacy, safety, and biomarker changes of B-cell activating factor and A proliferation-inducing ligand-targeted therapies in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials},
journal = {Journal of Nephrology},
year = {2026},
doi = {10.1093/joneph/aajaf002}
}
EUVIMED